Please login to the form below

Not currently logged in

BenevolentAI raises $115m to fund drug development


Its technology could cut the early stage drug discovery process by four years, says the company

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Amgen and Novartis migraine drug hits the mark again

Amgen flagAimovig will become the first CGRP receptor-targeting drug if it reaches market

Merck’s Keytruda meets survival challenge in NSCLC

merck-keytruda-pembrolizumab-melanomaData showed that almost 70% of patients on the combo were still alive after 12 months

AZ makes case for first-line Tagrisso therapy in lung cancer

AstraZeneca AZ headquarters London UKData shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Interim data suggested there was no improvement on disease-free survival compared to placebo

Merck’s Keytruda scores in frontline lung cancer yet again

merck-keytruda-pembrolizumab-melanomaDrug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

Incyte/Merck trial failure bodes ill for IDO class

Merck and Co - US headquartersThe much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...